George Simeon 4

What Happened
George Simeon, a reported 10% owner of Design Therapeutics (DSGN), was granted a derivative award of 30,000 shares on June 9, 2026. The award is reported at $0.00 (no cash paid at grant) and is recorded as a derivative acquisition (grant/option), not a share sale or open‑market purchase. This is an equity award rather than an exercised option or immediate purchase — not an outright cash investment.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-11 (appears timely under Form 4 rules).
• Instrument: Derivative award (option grant) for 30,000 shares; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The shares subject to the option vest in equal monthly installments over 12 months beginning June 9, 2026; in any case they will be fully vested by the Company’s next annual meeting of stockholders.
• Transaction code: A = Award/Grant (derivative).

Context
This filing documents a grant of option/derivative shares — not an exercise or sale — so there was no immediate transfer of cash or sale of shares. Awards to insiders (including large owners) are common as compensation or incentive and do not alone signal a buy or sell decision. As a 10% owner, Simeon is a significant stakeholder; the grant increases potential future ownership as the options vest, assuming they are later exercised.